Abbreviations: HL = Hodgkin lymphoma; NA = not assessable; NHL = non-Hodgkin lymphoma; RES = resistant; 1 CR = first CR; 2 CR = second CR.
Over the last 30 years, BEAM has been the most widely used conditioning regimen before autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) not achieving a CR, relapsing after chemotherapy, or with high-risk disease according to the International Prognostic Index. 1, 2, 3 Composed of drugs usually not employed in first-line therapy and not causing high toxicities in older people, 4 BEAM is generally very effective and well tolerated. Its most common toxicity consists of early oral and gastrointestinal mucositis, nausea, and vomiting; less frequent are lung, liver, and kidney toxicities.
With the aim of obtaining a higher anti-lymphoma activity and/ or reducing the toxic effects, in recent years the BEAM protocol has been modified by replacing Carmustine with Fotemustine 5 or high-dose Bendamustine, 6 reporting good efficacy and no high, acute, or short-term toxicity profile. Since BEAM requires Ara-C, which some chemotherapy regimens employ at high doses for the treatment of lymphoma, 7 we decided not to change the drugs of the BEAM scheme, but to increase the dosage of ARA-C from the standard 200-400 mg/sm/day to 2.000 mg/sm/day, administered in combination with the standard dose of Etoposide over three days instead of four (total ARA-C dose of 6.000 mg/sm) to reduce treatment-related toxicity.
In this retrospective analysis, we report and evaluate our singlecenter study of patients with HL and NHL who underwent auto-HSCT after having been treated with a modified BEAM (mBEAM) regimen inclusive of high-dose ARA-C. This study was undertaken in compliance with the Declaration of Helsinki and was approved by the Regione Marche local Ethics Committee. All patients provided written informed consent before starting treatment.
Between November 2007 and May 2012, 44 patients (8 with HL, 36 with NHL) were conditioned with mBEAM before undergoing auto-HSCT; follow-up period lasted until April 30, 2016, with a median follow-up of 74 months (range 37-96). At transplantation, patients were expected to have a Karnofsky performance status 460, together with adequate cardiac, liver, and lung function, and no infectious process.
The NHL group included patients in first CR with high-risk factors according to international prognostic indices 8, 9 or histologic types, patients in PR or resistant disease (RD) after first-line therapy, and with relapsed lymphoma in second CR, PR, or RD after second-line treatment; the HL group included patients in PR after first-line therapy, and with relapsed disease in second CR or PR (Table 1 ). All patients with B-cell NHL received R-CHOP-21, 6 or 8 cycles, as front-line therapy; four patients with Diffuse Large B-Cell Lymphoma (DLBCL) and two patients with Follicular Lymphoma (FL), due to high-risk factors, received six cycles of R-CHOP-21 followed by two cycles of R-IEV, with collection of HSC after the first cycle; two patients with mantle cell lymphoma (MCL) received four cycles of R-CHOP-21 followed by two cycles of R-DHAP, with collection of HSC after the second DHAP. Two patients with peripheral T-cell lymphoma were treated with six cycles of CHOP followed by two cycles including high-dose methotrexate and Ara-C, with collection of HSC after the first cycle. All patients with HL received ABVD chemotherapy as first-line therapy. The second-line/salvage chemotherapy, used before transplantation in patients with relapsed or refractory disease, was IEV or DHAP in both NHL and HL. The mBEAM protocol consisted of BCNU 300 mg/sqm on day − 5, Cytarabine 2000 mg/sqm and Vepesid 200 mg/sqm on days − 4, − 3, − 2 and Melphalan 140 mg/sqm on day − 1. One subject aged 470 years received ARA-C at a dose of 1000 mg/sqm. During the administration of Melphalan, cryotherapy was used to prevent oral mucositis. HSC were infused on day 0 through peripheral vein or central venous catheter. Peripheral HSC had been collected from all patients after administering chemotherapy and granulocyte growth factor Filgrastim or Lenograstim 5 μg/kg.
Patients received antimicrobial prophylaxis from day +1 consisting of mycostatin suspension 500 000 U swish and swallow three times a day, fluconazole 200 mg/day and levofloxacin 500 mg/day. Filgrastim 300 μg/day or Lenograstim 240 μg/day were administered to all patients starting on day +6 until neutrophil count was 42000 × 10 9 /L. Febrile neutropenic episodes were treated with broad-spectrum IV antibiotics, plus IV antifungal therapy if the fever persisted for more than 7 days. Patients received RBCs for hemoglobin level o 8.0 g/dL and random donor or single donor apheresis platelets for platelet count o 10 × 10 9 /L or clinical indication. While hospitalized, patients underwent daily assessment of symptoms and physical examination. To prevent Pneumocystis jiroveci and herpes virus infections, cotrimoxazole and acyclovir were administered for two months after discharge from the hospital.
Responses were evaluated according to the guidelines reported by Cheson et al. 10 Toxicities were evaluated in conformity with the National Cancer Institute's Common Terminology Criteria for Adverse Event version 3,0 (2003). All patients were examined with computed tomography (CT) and positron-emission tomography (PET) before and after auto-HSCT.
A descriptive analysis of all variables was performed. Using parametric and nonparametric statistical procedures, the possible interdependence between variables was evaluated and a P-value ⩽ 0.05 was considered significant.
Overall, the mBEAM scheme was well tolerated ( Table 2) . As expected, the most frequently observed non-hematologic toxicity was oral mucositis, mainly grade I/II (47%); compared to BEAM regimen 11 or variants like FEAM 5 and BeEAM, 6 mBEAM produced lower rates of total mucositis (61% vs 83-85%) and grade III/IV mucositis (14% vs 26-30%), probably due to the use of cryotherapy when administering high-dose Melphalan. 12 No patient experienced grade IV nausea and vomiting; grade III nausea and vomiting were observed in 14% of patients, while grade I/II in 57% of patients. Grade III/IV enterocolitis was experienced in 13% of cases, while grade I/II in 29% of cases. No patient showed significant liver or kidney toxicity. Lung toxicity and hepatic veno-occlusive disease never occurred. There were no toxic effects frequently associated with high-dose ARA-C like conjunctivitis, keratitis, or irreversible neuropathies. The number of febrile neutropenic episodes was low (43%), even lower compared to BEAM regimen and other variants. 1, 2, 5, 6 Transplantrelated mortality occurred in 1 case at high risk of infection: a urinary catheterized patient with paraparesis, and with relapsed/ resistant disease, died of septic shock from Pseudomonas infection on day +7. Another patient died of disease progression on day +47, before being discharged from the hospital. Aplasia after auto-HSCT was of short duration, and neutrophil and platelet recovery was comparable to what reported in other conditioning regimens; 1,2,5,6 most patients did not need red blood cell or platelet transfusions, if so the need was low (Table 2) . In a median follow-up period of 74 months, hematologic problems like delayed engraftment or myelodysplasia never occurred.
This research was undertaken to examine and evaluate the side effects of mBEAM. Although the case study was not large and included various histologic types of lymphoma, it is still possible to make some assessments of the efficacy of the therapy. Overall, all patients in CR before transplantation maintained CR. Among the 20 patients in PR, 12 (60%) achieved CR, 7 maintained PR, and 1 developed progressive disease. Among the 5 patients with RD, 2 achieved a partial response to Letter to the Editor treatment, 1 died of infection, and the other 2 did not respond to therapy and died of disease progression. Like mBEAM regimen induced a CR in most patients who had not achieved a complete regression of the disease with first or second-line therapy, chemosensitivity and histology affected the outcome as well. 13 All patients with DLBCL maintaining or achieving a CR are in continuous CR, while those maintaining or achieving a PR had a recurrence and died of disease progression. All patients with HL in PR achieved a CR, 2 patients relapsed, and 6 (75%) are in continuous CR, thus confirming the effectiveness of this treatment in patients with relapsing or refractory HL. 14 The best results were obtained in MCL, where the efficacy of high-dose ARA-C followed by auto-HSCT is well known:
15 the 2 patients, in CR before transplant, are both in continuous CR. Recurrence mostly occurred in patients with FL, namely 10 out of 13 (77%) after a median time of 19 months from transplantation (range 8-35); only 3 patients with FL in CR before transplant (1 in first CR, 2 in second CR) have maintained CR (Table 1 ). The patients with other NHLs have such a different histologic type of lymphoma that response to treatment cannot be assessed. Ten patients (six with DLBCL and four with HL) with bulky disease at diagnosis, and still slightly PET-positive before high-dose chemotherapy, underwent local radiotherapy after transplantation.
While BEAM conditioning regimen is still commonly used, it was demonstrated that its effectiveness can be enhanced, without increasing its toxicity, by employing Fotemustine or high-dose Bendamustine instead of Carmustine, or administering higher doses of the actual drugs required by the BEAM protocol: for this purpose, mBEAM with high-dose ARA-C has been proven safe and effective against different histologic types of lymphoma and, therefore, it may be put forward for consideration.
